Search - tctmd.com

Displaying 1 - 2 of 2

Sort: Relevancy | Date

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

News Conference News CRT 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

March 19, 2026

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.